Related Experiment Video
Updated: Jun 3, 2025
10:39
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
7.6K
Serum T2-High Inflammation Mediators in Eosinophilic COPD.
Andrius Januskevicius1,2, Egle Vasyle1, Airidas Rimkunas1
1Laboratory of Pulmonology, Department of Pulmonology, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania.
Biomolecules
|January 8, 2025
Summary
Eosinophilic chronic obstructive pulmonary disease (COPD) shares Type 2 (T2)-high inflammation mechanisms with asthma. Distinct serum mediator profiles in eosinophilic COPD may guide personalized treatment strategies.
Area of Science:
- Pulmonary Medicine
- Immunology
- Biomarker Discovery
Background:
- Eosinophils are key in asthma, and a subset of COPD patients exhibit eosinophilia (eCOPD).
- Understanding the inflammatory pathways in eCOPD is crucial for disease progression and treatment.
- Type 2 (T2)-high inflammation is implicated in asthma and potentially in eCOPD.
Purpose of the Study:
- To investigate serum levels of T2-high inflammation mediators in eCOPD patients.
- To compare these mediators with those in severe non-allergic eosinophilic asthma (SNEA) and healthy subjects.
- To identify potential biomarkers for T2-high inflammation in eCOPD and guide personalized therapy.
Main Methods:
- Serum samples from 8 eCOPD, 10 SNEA, and 11 healthy subjects were analyzed.
- Enzyme-linked immunosorbent assay (ELISA) was used to measure ten T2-high inflammation mediators.
- Statistical analysis identified significant differences and potential biomarkers.
Main Results:
- eCOPD patients showed distinct serum mediator profiles compared to SNEA patients, with elevated sIL-5Rα, MET, TRX1, ICTP, IL-4 and decreased eotaxin-1, sFcεRI.
- MET, ICTP, eotaxin-1, and sFcεRI demonstrated high sensitivity and specificity as eCOPD biomarkers.
- Combined analysis of IL-5, IL-25, sIL-5Rα, MET, and IL-4 effectively identified T2-high inflammation in eCOPD.
Conclusions:
- T2-high inflammation drives eosinophilic inflammation in both eCOPD and SNEA via similar pathways.
- Distinct mediator expression in eCOPD suggests an imbalance between T1 and T2 inflammatory pathways.
- Serum mediator analysis can aid in identifying T2-high inflammation and personalizing treatment for eCOPD.
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
01:26COPD: Management Using Bronchodilators and Corticosteroids
177
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
177
01:22Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
01:20Asthma: Pathogenesis and Management
346
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
346
01:17Drugs Used in Lower Respiratory Disorders: Overview
349
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
349